Epigenetic regulation of pharmacokinetic-related genes in human tissues

Research output: Contribution to journalReview article

Abstract

The translocation of drugs across biological membranes not only occurs via passive diffusion but also by transporter-mediated processes. Knowledge of tissue-specific drug transporter expression, as well as characterization of substrate drugs of individual transporters, leads to a better understanding of the role of these transporters in the pharmacokinetics of drugs. The ATP-binding cassette transporter family member breast cancer resistance protein (BCRP) is one of the most important intestinal efflux transporters involved in the intestinal absorption or permeability of drugs. A genetic variant in the BCRP, 421C>A, is a useful biomarker for explaining large interindividual differences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intragenotypic differences remain in spite of the incorporation of this genotype into the pharmacokinetics of SASP. Epigenetic regulation alters gene expression without changing DNA sequences. In epigenetic regulation, microRNAs (miRNAs) appear to be the most extensively investigated due to their important roles in the posttranscriptional regulation of mRNAs. Our study showed that miR-328 negatively regulates BCRP expression in human tissues, and the intestine-derived exosomal miR-328 levels positively correlated with the SASP area under the blood concentration-time curve. These results suggest that circulating intestinederived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in human intestines. A clearer understanding of epigenetic mechanisms regulating the expression of drug transporters will provide insights into novel approaches to individualized drug therapy.

Original languageEnglish
Pages (from-to)1391-1396
Number of pages6
JournalYakugaku Zasshi
Volume138
Issue number11
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Epigenomics
Pharmacokinetics
Breast Neoplasms
Pharmaceutical Preparations
Genes
Proteins
Intestines
Biomarkers
Sulfasalazine
ATP-Binding Cassette Transporters
Intestinal Absorption
Gene Expression Regulation
MicroRNAs
Permeability
Genotype
Drug Therapy
Messenger RNA
Membranes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Epigenetic regulation of pharmacokinetic-related genes in human tissues. / Hirota, Takeshi.

In: Yakugaku Zasshi, Vol. 138, No. 11, 01.01.2018, p. 1391-1396.

Research output: Contribution to journalReview article

@article{3a64e92bee1b4c6b927afc5f5bf0cd14,
title = "Epigenetic regulation of pharmacokinetic-related genes in human tissues",
abstract = "The translocation of drugs across biological membranes not only occurs via passive diffusion but also by transporter-mediated processes. Knowledge of tissue-specific drug transporter expression, as well as characterization of substrate drugs of individual transporters, leads to a better understanding of the role of these transporters in the pharmacokinetics of drugs. The ATP-binding cassette transporter family member breast cancer resistance protein (BCRP) is one of the most important intestinal efflux transporters involved in the intestinal absorption or permeability of drugs. A genetic variant in the BCRP, 421C>A, is a useful biomarker for explaining large interindividual differences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intragenotypic differences remain in spite of the incorporation of this genotype into the pharmacokinetics of SASP. Epigenetic regulation alters gene expression without changing DNA sequences. In epigenetic regulation, microRNAs (miRNAs) appear to be the most extensively investigated due to their important roles in the posttranscriptional regulation of mRNAs. Our study showed that miR-328 negatively regulates BCRP expression in human tissues, and the intestine-derived exosomal miR-328 levels positively correlated with the SASP area under the blood concentration-time curve. These results suggest that circulating intestinederived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in human intestines. A clearer understanding of epigenetic mechanisms regulating the expression of drug transporters will provide insights into novel approaches to individualized drug therapy.",
author = "Takeshi Hirota",
year = "2018",
month = "1",
day = "1",
doi = "10.1248/yakushi.18-00145",
language = "English",
volume = "138",
pages = "1391--1396",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "公益社団法人 日本薬学会",
number = "11",

}

TY - JOUR

T1 - Epigenetic regulation of pharmacokinetic-related genes in human tissues

AU - Hirota, Takeshi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The translocation of drugs across biological membranes not only occurs via passive diffusion but also by transporter-mediated processes. Knowledge of tissue-specific drug transporter expression, as well as characterization of substrate drugs of individual transporters, leads to a better understanding of the role of these transporters in the pharmacokinetics of drugs. The ATP-binding cassette transporter family member breast cancer resistance protein (BCRP) is one of the most important intestinal efflux transporters involved in the intestinal absorption or permeability of drugs. A genetic variant in the BCRP, 421C>A, is a useful biomarker for explaining large interindividual differences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intragenotypic differences remain in spite of the incorporation of this genotype into the pharmacokinetics of SASP. Epigenetic regulation alters gene expression without changing DNA sequences. In epigenetic regulation, microRNAs (miRNAs) appear to be the most extensively investigated due to their important roles in the posttranscriptional regulation of mRNAs. Our study showed that miR-328 negatively regulates BCRP expression in human tissues, and the intestine-derived exosomal miR-328 levels positively correlated with the SASP area under the blood concentration-time curve. These results suggest that circulating intestinederived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in human intestines. A clearer understanding of epigenetic mechanisms regulating the expression of drug transporters will provide insights into novel approaches to individualized drug therapy.

AB - The translocation of drugs across biological membranes not only occurs via passive diffusion but also by transporter-mediated processes. Knowledge of tissue-specific drug transporter expression, as well as characterization of substrate drugs of individual transporters, leads to a better understanding of the role of these transporters in the pharmacokinetics of drugs. The ATP-binding cassette transporter family member breast cancer resistance protein (BCRP) is one of the most important intestinal efflux transporters involved in the intestinal absorption or permeability of drugs. A genetic variant in the BCRP, 421C>A, is a useful biomarker for explaining large interindividual differences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intragenotypic differences remain in spite of the incorporation of this genotype into the pharmacokinetics of SASP. Epigenetic regulation alters gene expression without changing DNA sequences. In epigenetic regulation, microRNAs (miRNAs) appear to be the most extensively investigated due to their important roles in the posttranscriptional regulation of mRNAs. Our study showed that miR-328 negatively regulates BCRP expression in human tissues, and the intestine-derived exosomal miR-328 levels positively correlated with the SASP area under the blood concentration-time curve. These results suggest that circulating intestinederived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in human intestines. A clearer understanding of epigenetic mechanisms regulating the expression of drug transporters will provide insights into novel approaches to individualized drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=85055811067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055811067&partnerID=8YFLogxK

U2 - 10.1248/yakushi.18-00145

DO - 10.1248/yakushi.18-00145

M3 - Review article

C2 - 30381647

AN - SCOPUS:85055811067

VL - 138

SP - 1391

EP - 1396

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 11

ER -